Johnson & Johnson JNJ Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Sales to customers (Note 9) by Business | ||||||
| Innovative Medicine | $61.95B+8.2% | $60.4B+6.0% | $58.97B+4.6% | $57.99B+4.2% | $57.28B+4.3% | |
| MEDTECH | $34.41B+7.3% | $33.79B+6.1% | $33.18B+5.9% | $32.64B+5.6% | $32.06B+4.3% | |
| Sales to customers (Note 9) by Product | ||||||
| ADVANCED | $4.63B+3.4% | $4.58B+2.0% | $4.55B+1.1% | $4.5B-1.4% | $4.47B-3.6% | |
| CAPLYTA | $970M— | $700M— | $451M— | $211M— | $0— | |
| CARVYKTI | $2.12B+80.0% | $1.89B+96.0% | $1.67B+111% | $1.43B+118% | $1.18B+101% | |
| CONCERTA/Methylphenidate | $572M-6.5% | $584M-8.9% | $611M-7.7% | $613M-13.5% | $612M-18.8% | |
| CONTACT LENSES / OTHER | $3.96B+5.8% | $3.91B+4.7% | $3.84B+4.4% | $3.79B+4.2% | $3.74B+2.3% | |
| DARZALEX | $15.08B+23.4% | $14.35B+23.0% | $13.53B+21.5% | $12.88B+21.3% | $12.22B+20.1% | |
| EDURANT/rilpivirine | $1.54B+17.6% | $1.49B+16.8% | $1.43B+13.4% | $1.37B+11.9% | $1.31B+9.6% | |
| ERLEADA | $3.75B+21.8% | $3.57B+19.2% | $3.4B+18.8% | $3.25B+20.3% | $3.08B+21.6% | |
| GENERAL | $5.63B+5.1% | $5.56B+3.8% | $5.45B+1.6% | $5.4B+0.8% | $5.35B-0.5% | |
| HIPS | $1.7B+4.7% | $1.67B+2.2% | $1.65B+2.2% | $1.63B+1.1% | $1.63B+2.1% | |
| IMBRUVICA | $2.77B-6.4% | $2.82B-7.1% | $2.87B-7.3% | $2.93B-7.0% | $2.96B-8.0% | |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | $3.95B-3.0% | $3.81B-9.8% | $3.89B-6.8% | $4.01B-3.4% | $4.07B-1.4% | |
| KNEES | $1.62B+5.5% | $1.59B+2.7% | $1.55B+1.2% | $1.53B+0.5% | $1.53B+3.0% | |
| OTHER IMMUNOLOGY | $106M+2,550% | $61M+1,933% | $21M+320% | $10M+66.7% | $4M-50.0% | |
| OTHER INFECTIOUS DISEASES | $171M-54.4% | $175M-57.5% | $180M-88.4% | $189M-87.9% | $375M-73.4% | |
| OTHER NEUROSCIENCE | $1.03B-6.7% | $1.05B-10.8% | $1.06B-20.1% | $1.08B-21.7% | $1.11B-24.9% | |
| Other Oncology | $479M+4.6% | $501M+58.0% | $476M+96.7% | $468M+71.4% | $458M+47.7% | |
| Other | $3.72B+0.1% | $3.66B+208% | $3.69B+203% | $3.72B+195% | $3.72B+193% | |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | $1.62B-4.6% | $1.58B-7.8% | $1.6B-8.1% | $1.66B-5.0% | $1.7B-5.5% | |
| Remicade | $1.72B+5.2% | $1.77B+10.2% | $1.76B+4.9% | $1.7B-1.0% | $1.64B-8.3% | |
| RYBREVANT + LAZCLUZE | $850M+102% | $734M+124% | $640M+180% | $531M+227% | $421M+261% | |
| SIMPONI / SIMPONI ARIA | $2.66B+15.7% | $2.67B+21.8% | $2.62B+24.2% | $2.45B+10.2% | $2.3B+3.7% | |
| SPRAVATO | $1.84B+57.3% | $1.7B+57.5% | $1.49B+51.1% | $1.32B+48.6% | $1.17B+49.7% | |
| STELARA | $5.11B-46.4% | $6.08B-41.3% | $7.2B-33.1% | $8.3B-24.2% | $9.54B-12.2% | |
| SURGICAL | $1.59B+11.7% | $1.56B+10.3% | $1.51B+10.0% | $1.46B+6.8% | $1.43B+4.0% | |
| TALVEY | $529M+67.9% | $463M+61.3% | $399M+83.2% | $352M+122% | $315M+199% | |
| Tecvayli | $721M+27.2% | $670M+22.0% | $640M+21.0% | $598M+18.2% | $567M+21.9% | |
| TRAUMA | $3.21B+4.9% | $3.15B+3.2% | $3.1B+2.3% | $3.07B+1.9% | $3.06B+2.3% | |
| Tremfya | $5.81B+52.1% | $5.16B+40.5% | $4.52B+24.3% | $4.1B+16.6% | $3.82B+15.2% | |
| UPTRAVI | $1.93B+7.4% | $1.9B+4.7% | $1.88B+5.9% | $1.85B+7.9% | $1.8B+6.6% | |
| XARELTO | $2.59B+1.6% | $2.63B+11.0% | $2.62B+18.0% | $2.58B+14.4% | $2.55B+10.4% | |
| Sales to customers (Note 9) by Geography | ||||||
| Asia-Pacific, Africa | $14.31B+6.0% | $14.03B+3.2% | $13.79B+1.5% | $13.65B+0.6% | $13.5B-1.6% | |
| Europe | $22.27B+10.5% | $21.54B+6.5% | $20.86B+3.0% | $20.33B+1.3% | $20.16B+0.9% | |
| United States | $54.78B+7.4% | $53.75B+6.9% | $52.76B+7.4% | $51.96B+7.8% | $50.99B+7.8% | |
| Western Hemisphere, excluding U.S. | $5B+6.7% | $4.88B+3.4% | $4.74B-0.1% | $4.68B-1.3% | $4.69B+0.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Johnson & Johnson break its business down?
- Johnson & Johnson (JNJ) reports sales to customers (note 9) by business across 2 parts — Innovative Medicine and MEDTECH. Each is extracted from the segment footnotes and tracked over time.
- Where does Johnson & Johnson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Johnson & Johnson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
